Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

It’s Time to Be Brutally Honest About the Real Problem With Invesco QQQ Trust Series 1

By Josh Enomoto, InvestorPlace Contributor

During a bull market and with interest rates down, QQQ stock makes plenty of sense. However, it really looks like we’re going into the opposite environment.

Sundial Growers Is Technically Overdue for a Correction

By Josh Enomoto, InvestorPlace Contributor

Sundial Growers may have a fundamental case, but the fervor for SNDL stock is all about social media – and this fire could die out soon.

Shorting Marathon Digital Stock Might Make for a Good Bitcoin Hedge

By Josh Enomoto, InvestorPlace Contributor

As a speculative play before the institutional wave came in to drive up Bitcoin, MARA stock made sense for risk-takers. Today, the picture is much more complex.

9 Oil Stocks Betting on a Return to Travel and Normality

By Josh Enomoto, InvestorPlace Contributor

Although oil stocks go against the grain of clean and renewable energy, the circumstances of our times suggest that this sector has more enduring relevance than we previously thought.

Former Dumpster Fire Ocugen Makes a Compelling Bull Case

By Josh Enomoto, InvestorPlace Contributor

You don’t need to analyze much to realize that OCGN stock is an incredibly risky trade. Nevertheless, the political necessity of an effective vaccine against the evolving nature of Covid-19 gives Ocugen surprising relevancy.

Load More